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ARTICLE
Submicroscopic Deletion in Patients with Williams-Beuren
Syndrome Inﬂuences Expression Levels of the Nonhemizygous
Flanking Genes
Giuseppe Merla, Ce´dric Howald, Charlotte N. Henrichsen, Robert Lyle, Carine Wyss,
Marie-The´re`se Zabot, Stylianos E. Antonarakis, and Alexandre Reymond
Genomic imbalance is a common cause of phenotypic abnormalities. We measured the relative expression level of genes
that map within the microdeletion that causes Williams-Beuren syndrome and within its ﬂanking regions. We found,
unexpectedly, that not only hemizygous genes but also normal-copy neighboring genes show decreased relative levels
of expression. Our results suggest that not only the aneuploid genes but also the ﬂanking genes thatmap severalmegabases
away from a genomic rearrangement should be considered possible contributors to the phenotypic variation in genomic
disorders.
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Segmental aneuploidies (i.e., gain or loss of subchromo-
somic DNA fragments) are important contributors to hu-
man diseases1 and, potentially, to phenotypic variation,2,3
as well as a major force of evolutionary changes.4–9 There
is evidence that such genomic insertions and deletions
contribute to phenotypic differences by modifying the ex-
pression levels of genes within the aneuploid segments.10–
13 We hypothesize that these rearrangements also induce
altered expression of the genes that lie near the break-
points, although these do not vary in copy number; this
effect could be mediated by disturbances of the copy num-
ber of long-range cis regulatory elements.14–17
To test this hypothesis, we assessed whether the human
chromosome 7 (HSA7) recurrent DNA deletion causing
Williams-Beuren syndrome (WBS [MIM 194050])18 inﬂu-
ences the transcription levels of both the hemizygous
genes within the deleted region and the nonhemizygous
genes in the WBS ﬂanking regions. WBS is a neurodevel-
opmental disorder characterized by numerous clinical as-
pects, including mental retardation with a unique cogni-
tive and personality proﬁle.19 Its incidence is estimated to
be between 1:7,500 and 1:20,000, and sporadic de novo
inheritance is usual.20–22
Material and Methods
Cell Culture, RNA, and cDNA Preparations
Human skin ﬁbroblasts and lymphoblastoid cell lines were grown
in HAM F-10 or RPMI 1640 media, respectively, supplemented
with 10% fetal bovine serum and 1% antibiotics (Invitrogen).
Total RNA was prepared from logarithmic growth–phase cells,
with the use of RNeasy Mini Kit (Qiagen), in accordance with the
manufacturer’s instructions. After DNAse treatment (Qiagen), the
quality of all RNA samples were checked using an Agilent 2100
Bioanalyzer (Agilent Technologies). Total RNA was converted to
cDNA with the use of Superscript II (Invitrogen) primedwith poly
d(T). For each cell line included in the study, 4.5 mg of total RNA
was converted to cDNA in three individual reactions; these were
then pooled and were diluted 1:14.
Sample Population
Lymphoblastoid cell lines from10 individuals withWBS and from
40 control individuals, as well as skin ﬁbroblasts from 7 control
individuals, were acquired from the cell culture collection of the
Coriell Institute for Medical Research, and skin ﬁbroblasts from
14 individuals with WBS and from 6 control individuals were
obtained from the cell culture collections of the Centre de Bio-
technologie Cellulaire, Hospices Civils de Lyon, Hoˆpital De-
brousse, in Lyon, France. One more control was received from
the Galliera Genetic Bank in Genova, Italy (table 1). Appropriate
informed consent was obtained for each sample by the physicians
in charge. DNA was extracted from each cell line of the sample
population, with the use of PureGene (Gentra Systems), in ac-
cordance with the manufacturer’s instructions. We assayed each
DNA with a quantitative PCR approach, using SybrGreen dye and
probes, mapping the region from the BAZ1 locus to the CYLN2
locus and the ﬂanks of the commonly deleted region,23 to deter-
mine the size of the deletions and to ensure (1) that none of the
patients with WBS presented an atypical deletion23–29 or an in-
version at 7q11.23 18,30 and (2) that none of the controls were
hemizygous for that same region. The results are presented in
table 2.
To make sure that differences in expression levels measured in
lymphoblastoid cells were not merely due to transformation, we
established six lymphoblastoid cell lines from two blood samples
collected at 1-wk intervals from the same individual, after in-
formed consent. We measured expression levels of 25 HSA21
genes (ITBG2, CBS, APP, PFKL, U2AF1, PRDM15, LSS, PDXK,
SLC19A1, SLC37A1, PWP2H, MCM3AP, GART, CBR1, TMEM1,
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Table 1. Cell Lines Employed
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3. Assayed Genes, Primers, Probes,
and Efﬁciencies
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2. Genotyping of Cell Lines
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
BTG3, DSCR1, ETS2, IFNAR2, ANKRD3, WRB, GABPA, SON,
IFNAR1, and CCT8) that show a large variation in transcript levels
in the normal population and found no signiﬁcant differences in
their expression levels in the assayed samples (Pearson 0.8 ! r !
[mean 0.87]; ). The observed differences correspond0.92 P ! .001
to the experimental variation we measure between replicates.
Real-Time Quantitative PCR and Data Analysis
We opted for Taqman real-time quantitative PCR, to measure any
small differences in gene expression levels. Primers and probes
were designed using the PrimerExpress program (Applied Biosys-
tems), with default parameters in every case for all the conﬁrmed
genes mapping on HSA7, from the centromere to the beginning
of band 7q21.11. They can be divided into three groups of genes:
23 HSA7 test genes that are hemizygous in patients with WBS, 2
genes mapping in the low-copy repeats (LCRs) ﬂanking the WBS
deletion, and 24 HSA7 test genes that are nonhemizygous in pa-
tients with WBS. We also designed assays in 2 HSA7p genes, in
13 control genes, and in 3 normalization genes. The complete
list of tested genes, their accession numbers and mapping posi-
tions, and the primers and probes used are indicated in table 3.
Amplicon sequences were checked by both BLAST and BLAT
against the human genome, to ensure speciﬁcity. Whenever pos-
sible (in 94% of cases), oligos were designed to span an intron.
Non–intron-spanning assays were tested in standard  reverse
transcriptase reactions of RNA samples for genomic contamina-
tion; in all cases, no ampliﬁcation was observed in the absence
of reverse transcriptase. High-performance liquid chromato-
graphy–puriﬁed, FAM-TAMRA–labeled, double-dye Taqman
probes and qPCR mastermix (RT-QP2X-03) were obtained from
Eurogentec.
The efﬁciency of each Taqman assay was measured using a
dilution series of ﬁbroblast cDNA and lymphoblastoid cells or a
pool of cDNA samples of brain, liver, and testis, as described else-
where31 (see table 3 for results). A working Taqman assay was
obtained for 57 (85%) of the 67 assayed genes. We were unsuc-
cessful for RCP9, RABGEF1, FKBP6, FZD9, WBSCR14, CLDN4,
MK-STYX, FGL2, AIP, and GRM3. Six more genes (TPST1,
WBSCR17/GALNT9, CALN1, WBSCR27, WBSCR28, andWBSCR16)
were excluded because of a lack of expression in both ﬁbroblasts
and lymphoblastoid cell lines (see efﬁciencies in table 3). Note
that TRIM50/73/74, ATP50, SIM2, and UFD1L are not expressed
in skin ﬁbroblasts, whereas WBSCR24, WBSCR18, CLDN3, ELN,
CACNA2D1, GABPA, IFNGR2, and DGCR8 are not expressed in
lymphoblastoids. Thus, in at least one of the two studied cell
lines, we were able to assess the relative expression level (REL) of
76% (51/76) of the selected genes, a proportion signiﬁcantly
above the one expected with genomewide technologies. Typi-
cally, microarrays hybridized with ﬁbroblast or lymphoblastoid
cell cDNA measure the expression of 30%–40% of human genes.
All RT-PCRs were performed in a 10-ml ﬁnal volume and in ﬁve
replicates per sample and were set up in a 384-well plate format,
with the use of a Biomek 2000 robot (Beckman). They were run
in an ABI 7900 Sequence Detection System (Applied Biosystems)
with the following ampliﬁcation conditions: 50C for 2min, 95C
for 10 min, and 50 cycles at 95C for 15 s and 60C for 1 min.
Each plate contained the appropriate normalization genes to con-
trol for any variability between the different plate runs.
Raw threshold-cycle (CT) values were obtained using SDS2.2
(Applied Biosystems). To calculate the normalized relative ex-
pression ratio between individuals with WBS and controls, we
followed methods described elsewhere.31 We exploited the ge-
Norm method32 to select the three normalization genes: AGPAT1,
EEF1A1, and PSMA5. They were used to normalize input cDNA
for each sample, whereas mixes of 40 lymphoblastoid and 12
ﬁbroblast control-cell-line cDNA samples (table 1) were used to
deﬁne normal RELs.
Results
We used the high sensitivity of real-time quantitative PCR
to accurately measure the expression of all the HSA7q
genes mapping in the region 11.9 Mb downstream (band
7q21.11) to 8.4 Mb upstream (centromere position) of the
WBS deleted region, in which we could design a working
Taqman assay (i.e., efﬁciency 0.95 and 1.05 for ex-
pression in ﬁbroblasts and/or lymphoblastoid cell lines)
(see “Material and Methods” and table 3 for details). These
genes can be divided into 17 HSA7q hemizygous genes
that map within the WBS deletion, 14 HSA7q nonhemi-
zygous genes, and 2 genes that map within the LCR ﬂank-
ing the deletion. This panel of genes was completed with
2 HSA7 nonhemizygous genes that map on the short arm
of the chromosome (band 7p11.2) and 19 control, non-
HSA7 genes. We compared the mRNA expression levels of
these genes in nontransformed skin ﬁbroblast cells ob-
tained from 14 subjects with WBS and from 14 controls
and in transformed lymphoblastoid cells obtained from
10 subjects with WBS and from 11 controls (see table 1
for cell lines; see table 2 for genotyping23; and see table 3
for a complete list of assayed genes, primers, and probes).
The results of these analyses are summarized in table 4.
We found extensive variability in gene RELs in humans
(table 4, ﬁg. 1, and data not shown), which is consistent
with previous reports.16,17,33 In the population with WBS,
all but two of the genes that map to the common deletion
interval and that are hemizygous in patients with WBS
show average relative expression levels (ARELs) that are
approximately half of the normal ARELs (see table 4 and
ﬁgs. 1C, 1D, and 2), which is consistent with partial results
published elsewhere.34 In contrast, the control genes show
no signiﬁcant variation in RELs between the patients and
the controls (see table 4 and ﬁgs. 1A, 1B, and 2). Inter-
estingly, one hemizygous gene per cell type deviates from
Table 4. ARELs
Gene Categorya
Controls WBS WBS/Controls
Pairwise t
Test PAREL SD AREL SD t Test P
Mann-
Whitney
P
AREL
Ratiob
Lymphoblastoid cell lines:
GBAS 2 1.38 .37 1.01 .20 .02 .04 .74 …
PSPH 2 1.19 .31 .99 .37 .23 .16 .83 …
ZFD25 2 1.15 .28 .98 .33 .24 .15 .85 …
VKORC1L1 2 1.31 .35 1.05 .42 .15 .15 .80 …
GUSB 2 .95 .18 .92 .36 .82 .35 .97 …
ASL 2 .81 .15 1.29 .39 .004 .004 1.59 …
KCTD7 2 .91 .42 .36 .08 .004 .005 .39 …
NM_017994 2 .99 .19 .89 .14 .18 .13 .89 …
RSAFD1/NM_018264 2 1.13 .23 1.20 .53 .71 .54 1.06 …
AUTS2 2 .57 .50 .20 .21 .06 .06 .35 …
WBSCR20 6 .63 .09 .30 .11 1.0#1056 .0003 .48 …
TRIM50/73/74 6 1.07 .71 .71 .29 .22 .36 .66 …
BAZ1B 1 2.29 .92 .64 .22 .0006 .0004 .28 …
BCL7B 1 .74 .31 .26 .09 .002 .0004 .35 …
TBL2 1 .64 .14 .24 .08 5.0#1056 .0003 .38 …
WBSCR24 1 NE NE NE NE NE NE NE …
WBSCR18 1 NE NE NE NE NE NE NE …
WBSCR22 1 .65 .20 .28 .09 .0003 .0003 .43 …
STX1A 1 .92 .33 .27 .10 .0003 .0003 .29 …
WBSCR21 1 1.18 .48 .44 .15 .001 .0009 .37 …
CLDN3 1 NE NE NE NE NE NE NE …
ELN 1 NE NE NE NE NE NE NE …
LIMK1 1 2.24 .80 .42 .14 .0001 .0004 .19 …
WBSCR1/EIF4H 1 .73 .15 .25 .09 1.1#1056 .0003 .34 …
WBSCR5 1 .68 .21 .24 .07 .0001 .0003 .36 …
RFC2 1 .86 .28 .40 .12 .0009 .0003 .46 …
CYLN2 1 .81 .37 .23 .08 .001 .0003 .29 …
GTF2IRD1 1 .28 .21 .32 .19 .68 .65 1.14 …
GTF2I 1 .95 .19 .35 .11 2.0#1056 .0003 .37 …
HIP1 2 .90 .46 .42 .17 .015 .02 .47 …
RHBDL7/NPD007 2 .62 .23 .50 .20 .23 .31 .80 …
POR 2 .56 .14 .50 .15 .37 .71 .89 …
MDH2 2 .86 .08 1.05 .14 .002 .005 1.23 …
DTX2 2 .78 .29 .83 .17 .62 .18 1.07 …
CACNA2D1 2 NE NE NE NE NE NE NE …
USP18 C 1.19 .71 1.32 .62 .26 .66 1.11 …
DGCR8 C NE NE NE NE NE NE NE …
ATP50 C .45 .11 .47 .16 .71 .21 1.05 …
B2M C .63 .12 .60 .28 .76 .54 .95 …
DSCR2 C 1.58 .59 1.99 .95 .29 .45 1.25 …
IFNAR1 C 1.08 .33 1.34 .66 .28 .54 1.25 …
BTG3 C .79 .25 .56 .19 .04 .02 .71 …
IFNGR2 C NE NE NE NE NE NE NE …
GABPA C NE NE NE NE NE NE NE …
IL10RB C .94 .11 1.19 .65 .24 .65 1.28 …
SON C 1.00 .26 .86 .27 .26 .49 .86 …
SIM2 C 1.04 .47 .81 .55 .35 .31 .78 …
UFD1L C 1.51 .49 1.84 .40 .04 .08 1.22 …
Nonhemizygous:
Allc 2 .89 .23 .78 .35 … … .88 .20
Centromerec 2 .98 .23 .86 .39 … … .88 .32
Telomere 2 .74 .14 .66 .27 … … .89 .51
Closed 2 .81 .23 .58 .34 … … .71 .04
LCRs 6 .85 .30 .51 .29 … … .60 .03
Hemizygous 1 1.00 .60 .33 .12 … … .33 .0005
Controls C 1.00 .34 1.12 .51 … … 1.12 .16
Skin ﬁbroblasts:
GBAS 2 .99 .35 .91 .23 .53 .89 .92 …
PSPH 2 .94 .34 .76 .32 .18 .31 .80 …
ZFD25 2 .90 .37 .78 .38 .45 .34 .87 …
(continued)
Table 4. (continued)
Gene Categorya
Controls WBS WBS/Controls
Pairwise t
Test PAREL SD AREL SD t Test P
Mann-
Whitney
P
AREL
Ratiob
VKORC1L1 2 1.10 .33 1.00 .41 .55 .67 .92 …
GUSB 2 .95 .31 1.06 .16 .29 .31 1.11 …
ASL 2 1.11 .32 .85 .23 .03 .08 .77 …
KCTD7 2 .87 .43 .59 .13 .06 .13 .68 …
NM_017994 2 1.09 .24 1.02 .17 .44 .69 .94 …
RSAFD1/NM_018264 2 .98 .19 .93 .16 .50 .47 .95 …
AUTS2 2 1.02 .46 .72 .43 .11 .13 .70 …
WBSCR20 6 .54 .21 .26 .04 .002 .0005 .48 …
TRIM50/73/74 6 NE NE NE NE NE NE NE …
BAZ1B 1 1.02 .34 .31 .15 8.5#1056 .00001 .31 …
BCL7B 1 .95 .37 .27 .06 4.6#1055 .00001 .28 …
TBL2 1 .91 .30 .30 .08 1.7#1055 .0001 .32 …
WBSCR24 1 .62 .45 .18 .04 .006 .0001 .29 …
WBSCR18 1 1.02 .33 .34 .13 9.9#1056 .00001 .34 …
WBSCR22 1 .92 .22 .29 .07 3.9#1057 .00001 .32 …
STX1A 1 .98 .59 .22 .06 .001 .0001 .23 …
WBSCR21 1 .92 .33 .27 .08 1.9#1055 .0001 .29 …
CLDN3 1 .81 .56 .38 .17 .03 .04 .47 …
ELN 1 1.60 1.63 1.74 1.74 .85 .62 1.08 …
LIMK1 1 .94 .21 .26 .11 2.5#1058 .00001 .28 …
WBSCR1/EIF4H 1 .91 .31 .28 .08 1.5#1055 .00001 .30 …
WBSCR5 1 1.15 .48 .38 .12 .0001 .0001 .33 …
RFC2 1 .65 .24 .17 .06 2.4#10-5 .00001 .27 …
CYLN2 1 .61 .19 .18 .05 6.7#10–6 .00001 .29 …
GTF2IRD1 1 .69 .27 .16 .04 3.2#1055 .00001 .24 …
GTF2I 1 1.36 .38 .72 .18 8.3#1055 .0001 .53 …
HIP1 2 .51 .29 .29 .09 .03 .04 .56 …
RHBDL7/NPD007 2 .88 .38 .64 .17 .06 .10 .73 …
POR 2 .81 .23 .50 .10 .0006 .005 .62 …
MDH2 2 1.09 .18 .90 .16 .01 .01 .83 …
DTX2 2 1.06 .27 .95 .20 .29 .44 .90 …
CACNA2D1 2 1.01 .61 .94 .62 .80 .98 .94 …
USP18 C 1.05 .55 1.24 .47 .36 .21 1.18 …
DGCR8 C .98 .63 .94 .32 .83 .84 .95 …
ATP50 C NE NE NE NE NE NE NE …
B2M C 1.07 .57 1.15 .35 .67 .29 1.08 …
DSCR2 C .87 .26 .80 .28 .53 .56 .92 …
IFNAR1 C .85 .45 .82 .20 .42 .49 .97 …
BTG3 C .86 .44 .60 .21 .08 .09 .69 …
IFNGR2 C .93 .27 .85 .22 .41 .56 .91 …
GABPA C 1.11 .57 1.37 .61 .30 .31 1.23 …
IL10RB C 1.03 .40 1.25 .29 .15 .10 1.21 …
SON C .61 .24 .43 .10 .03 .03 .71 …
SIM2 C NE NE NE NE NE NE NE …
UFD1L C NE NE NE NE NE NE NE …
Nonhemizygous:
Allc 2 .96 .16 .80 .23 … … .84 .0003
Centromerec 2 1.00 .09 .87 .17 … … .87 .03
Telomere 2 .89 .22 .71 .28 … … .79 .004
Closed 2 .94 .19 .74 .24 … … .78 .0001
LCRs 6 .54 .21 .26 .04 … … .48 .002
Hemizygous 1 .94 .26 .38 .37 … … .40 7.3#1059
Controls C .94 .15 .95 .30 … … 1.01 .87
NOTE.—NE indicates that the gene is not expressed in this cell line.
a 1p HSA7 hemizygous in WBS; 2p HSA7 nonhemizygous in WBS; 6p genes mapping in the LCR ﬂanking the WBS commonly
deleted region (i.e., present in six copies/genome); C p control genes.
b Ratio of ARELs of patients with WBS compared with controls.
c Does not take into account GBAS and PSPH, the two genes mapping to the HSA7 short arm.
d Close nonhemizygous genes on both the centromeric and the telomeric side.
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Figure 1. REL distributions measured in 14 patients with WBS and in 14 control skin ﬁbroblasts. REL boxplots are shown for control
genes (IFNGR2 [A] and USP18 [B]), for hemizygous genes that map to the commonly deleted WBS interval (LIMK1 [C] and BAZ1B [D]),
for nonhemizygous genes that map to the ﬂank of the commonly deleted WBS interval (HIP1 [E], NM_017994 [F], and POR [G]), and
for LCR genes that map to the repeats ﬂanking the WBS deletion (WBSCR20 [H]). Asterisks indicate and double asterisks indicateP ! .04
, at both t and Mann-Whitney tests.P ! .005
this general pattern; the GTF2IRD1 gene in lymphoblas-
toid cells and the ELN gene in ﬁbroblasts show no signif-
icant changes in their ARELs between control and patient
samples.
ELN haploinsufﬁciency has been linked to supravalvular
aortic stenosis (SVAS) and to other stenoses.35–39 Here, we
ﬁnd that the REL of the ELN gene in skin ﬁbroblasts is
not signiﬁcantly different between the control population
and the patients with WBS (  0.31;fibroAREL p 1.08
) (table 4). This result is in agreement with thosePp .85
obtained using microarray technology (A. Quattrone and
G. Merla, unpublished data) but differs substantially from
the one described elsewhere.40 This discrepancy might be
due to the very limited number (only one) of samples
www.ajhg.org The American Journal of Human Genetics Volume 79 August 2006 337
Figure 2. Differences of expression levels in patients with WBS and in controls. Ratio of ARELs from 14 patients with WBS and from
14 controls, measured in skin ﬁbroblasts. Left to right, Two HSA7 short-arm genes, HSA7 long-arm genes from the centromere to the
telomere, followed by the control genes (squares) and the mean (disks) of each tested gene category. Nonhemizygous WBS HSA7 genes
(blue) map centromerically (cen) or telomerically (tel) of the deletion. LCR p Gene mapping to the repeats ﬂanking the WBS deletion
(green). hemizygous p Hemizygous WBS HSA7 genes (red). controls p Control genes mapping outside HSA7 (yellow). A schematic
representation (not to scale) of the HSA7 cytogenetic bands in which the assessed genes map is presented in the lower part of the
graph. Asterisks indicate and double asterisks indicate , at both t and Mann-Whitney tests for individual genes andP ! .05 P ! .001
also at pairwise t test for categories. A double number sign (##) indicates that the t and Mann-Whitney tests are signiﬁcant at P !
and , respectively (see table 4 for details)..001 P ! .005
Table 5. Numbers of UniGene ESTs for
TRIM50 and WBSCR20
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
studied and/or to the less sensitive method used in the
latter study.40 As demonstrated by the large SD (table 4),
we observe a large variation in relative expression of ELN
in the patients with WBS. It is, therefore, possible that the
incomplete penetrance of the SVAS phenotype is corre-
lated with the REL of ELN41,42—that is, that patients who
are under a compensatory mechanism of expression are
less likely to present the phenotype. Consistently, the
AREL of the ELN gene in patients with WBS with SVAS
(  1.08) is lower than it is in patients withARELp 1.15
WBS without this phenotype (  1.97); how-ARELp 2.56
ever, this difference is not signiﬁcant. To conﬁrm this hy-
pothesis, we will need to measure the relative expression
of this gene in a large number of patients.
A mouse model and recent functional data suggest that
hemizygosity of CYLN2 and WBSCR14 might contribute
to the cognitive proﬁle and to impaired glucose tolerance
or silent diabetes, respectively, in patients with WBS.43–46
Whereas the study of patients with WBS with atypical
deletion suggests that hemizygosity of GTF2IRD1 and
GTF2I is linked to their visual spatial processing deﬁcits,23–
29,47,48 Gtf2ird1-null mice display craniofacial abnormali-
ties, thus suggesting a possible link between hemizygosity
of GTF2IRD1 and craniofacial abnormalities displayed in
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Figure 3. Schematic partial transcript map of the 7q11.23 region in normal chromosome (top) and in chromosomes bearing the classical
WBS 1.55-Mb (center) and 1.84-Mb (bottom) deletions. The different centromeric (c), middle (m), and telomeric (t) duplicons within
the LCRs are represented by speciﬁc arrows that specify their relative orientation and type. Gray arrow indicates BLOCK-A (A); striped
arrow indicates BLOCK-B (B); and white arrow indicates BLOCK-C (C). Genes are depicted by black rectangles, with their names given
above.
patients with WBS.49 In this article, we ﬁnd that the rel-
ative expression of GTF2IRD1 is signiﬁcantly decreased in
the ﬁbroblasts of patients with WBS ( fibroAREL p 0.24
0.02; ) but is not affected in lymphoblastoid5Pp 3.2# 10
cell lines (  0.21; ) (table 4).lymphoAREL p 1.14 Pp .68
Thus, we cannot assess the contribution of the GTF2IRD1
gene to the WBS cognitive phenotype, because its expres-
sion might be under special control in the CNS of patients
with WBS.
Remarkably, a signiﬁcant decrease in relative expression
was observed for the nonhemizygous genes ASL, KCTD7,
HIP1, POR, and MDH2, which map outside the common
deletion region (see table 4 and ﬁgs. 1E–1G and 2), al-
though the decrease was not as large as that observed for
hemizygous genes. This decrease is signiﬁcant even if we
consider all the tested nonhemizygous genes in ﬁbroblasts
mapping to HSA7q or the subset of closest-tested hemi-
zygous genes in lymphoblastoid cells (table 4 and ﬁg. 2).
Two of the tested genes, WBSCR20 and TRIM50, map
in the LCRs. Three highly similar copies (WBSCR20A,
WBSCR20B, and WBSCR20C and TRIM50, TRIM73, and
TRIM74; 198% identity each) of each of these genes are
present within the studied region (see table 3 and ﬁg. 3).50
TRIM50 (also known as “TRIM50A”) and WBSCR20A map
centromerically to FKBP6 within repeat BLOCK-C-mid;
TRIM73 (also known as “TRIM50B”) and WBSCR20B
map telomerically to FKBP6T2 in BLOCK-C-tel; whereas
TRIM74 (also known as “TRIM50C”) and WBSCR20C map
to the BLOCK-C-cen interval centromeric to FKBP6T1 (see
schematic representation in ﬁg. 3).50–52 WBSCR20A and
TRIM50, only one copy of each gene, are hemizygous in
patients with WBS (ﬁg. 3).18 We designed a Taqman assay
able to simultaneously recognize all three copies and col-
lectively measure the RELs of all copies. Both WBSCR20A/
B/C and TRIM50/73/74 exhibit RELs decreased by about
one-half and one-third, respectively, in patients withWBS
(see table 4 and ﬁgs. 1H and 2), a result that deviates no-
ticeably from the theoretically predicted decrease of 17%.
It is possible that different levels of expression of the three
copies account for this discrepancy. Consistently, the
study of UniGene clusters suggests that TRIM50 is ex-
pressed more than TRIM73 and TRIM74 together. Con-
versely, WBSCR20A is not expressed at a higher level than
the B and C copies (table 5). These observations suggest
that the decrease in relative expression cannot be ex-
plained solely by copy-speciﬁc expression-level differ-
ences. A possible explanation would be that the number
of BLOCK-C repeats is polymorphic in the population;
however, published results suggest only that the number
of BLOCK-A and BLOCK-B copies are polymorphic (see
ﬁg. 3).52,53 Thus, our results are consistent with the hy-
pothesis that the nondeleted copies in cis with the dele-
tion are possibly affected in their expression.
Discussion
Our results suggest that, in genomic disorders, not only
the aneuploid genes but also the normal-copy genes that
map close to a deletion should be considered as candidate
genes for features of these abnormal phenotypes, although
we cannot exclude the possibility that what we observe
here is only a 7q11.23 region–speciﬁc phenomenon. For
example, the HIP1, POR, and KCTD7 genes, located at dis-
tances of 0.7, 1.2, and 6.5 Mb from the WBS region, re-
spectively (table 1), show signiﬁcantly disregulated pat-
terns (t test and , , and4Pp .015 Pp .025 Pp 6.3# 10
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, respectively; Mann-Whitney test3Pp 3.8# 10 Pp
and , , and , re-3 3.025 Pp .04 Pp 5.1# 10 Pp 4.7# 10
spectively) (table 4) and are thus good candidates for in-
volvement in certain WBS phenotypic features. Remark-
ably, it appears that this deregulation is more pronounced
for genes mapping closer to the breakpoint (ﬁg. 2). This
ﬁnding also suggests the presence of very distant long-
range cis-regulatory elements—to an extent, undescribed
elsewhere—and substantiates the notion that functional
gene domains extend way beyond their transcription
units.54 Although this phenomenon was observed in both
a transformed and an untransformed cell line, we cannot
be certain that the relative expression pattern is the same
in the tissues affectedwith the different phenotypes.How-
ever, data obtained elsewhere, from partial Down syn-
dromemousemodels, have shown that relative expression
from aneuploid genes is signiﬁcantly similar across dif-
ferent tissues and developmental stages.10,11
Even though deletions or duplications of large genomic
regions result in signiﬁcant gene expression changes, our
results show that the changes are not always directly cor-
related to copy number, which suggests an underlying
complexity that might involve the size of the deletion,
the altered structure of chromatin, a dosage-compensation
mechanism, or a combination of these factors. In partic-
ular, we identiﬁed two transcripts within the commonly
deleted WBS region for which there were no signiﬁcant
expression differences. Our observations also suggest that
changes in the expression levels of genes neighboring
large-scale copy-number polymorphisms2,3,55–57mightplay
an important role in phenotypic variation in normal pop-
ulations and, possibly, in evolution.
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